Realtime AI News
Isomorphic Labs raises $5B Series C to push drug candidates toward clinical trials
Isomorphic Labs, the AI drug-discovery company spun out of Google DeepMind, has raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital. The company says its programs have shown positive preclinical results in oncology and immunology, and the new capital will help push candidates toward clinical trials.

Isomorphic Labs, the AI drug-discovery company spun out of Google DeepMind in 2021, has raised $5 billion in a Series C round as it works to push its drug candidates into clinical trials, TechCrunch reported on November 17.
The round was co-led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz and others participating. All existing backers joined as well, including Alphabet's GV and CapitalG, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund. Isomorphic did not disclose a valuation; Bloomberg reported earlier this month that the company was seeking to raise at a $50 billion valuation.
The company builds an AI drug-design engine that runs a range of simulation models across chemistry to design candidate medicines. Its work builds on DeepMind's AlphaFold protein-folding system, and the company says its programs have produced positive preclinical results in oncology and immunology.
On the commercial side, Isomorphic has signed deals with pharmaceutical companies including Eli Lilly, Novartis and Johnson & Johnson. The new capital follows a $2.1 billion Series B in May and will go toward further developing the drug-design engine and extending into more types of medicine.
It is also the first raise since founder and CEO Demis Hassabis stepped down as head of DeepMind to focus on drug discovery, moving into a chairman role at the lab. Hassabis and former DeepMind director John Jumper shared the Nobel Prize in chemistry for AlphaFold, which predicts a protein's 3D structure from its genetic sequence alone.
A single $5 billion round is rare even by AI standards, and it signals that investors are still willing to fund the long, expensive path from computational design to clinical assets. The open question is whether structure prediction and molecular simulation can reliably translate into molecules that survive human trials.
What to watch next is whether Isomorphic moves its preclinical candidates into Phase 1 studies, and whether the reported $50 billion valuation is confirmed in later disclosures. Either would say a lot about how close AI drug design has come to producing real medicines rather than promising models.
Why it matters
The raise moves AI drug discovery from a modelling story to a clinical-asset test; progress into Phase 1 would reset how investors value the sector.
Nearby Updates
All11/17, 22:58
Plaid launches Agent Detection to tell humans from AI agents in finance
Plaid has launched Agent Detection, a product that tells banks and fintechs whether a financial interaction is driven by a human or an AI agent, and which AI provider the agent belongs to. In live-traffic tests the company says it flagged 2.3 times more agent sessions than competing tools without more false positives.
11/17, 23:00
ExpertFile launches ProfileIQ, an AI agent that drafts expert profiles for search and AI citation
ExpertFile has launched ProfileIQ, an AI agent that cross-checks multiple sources to draft expert profiles with topic tags, schema markup, ORCID matching and a human review step. It is available now and included for all ExpertFile clients, aimed at making institutional experts discoverable by AI answer engines.
11/17, 22:05
Nvidia Forms Board National Security Committee to Oversee Export Controls
Nvidia has created a standing board committee with direct oversight of national security policy, export control compliance and global trade risk, meeting at least quarterly. Announced hours before the company's third-quarter earnings call, it is interim CEO Colette Kress's first major action, taken amid congressional scrutiny of Jensen Huang and U.S. chip export policy.
11/17, 22:04
AI Travel Agent Vayo Adds Booking, Moving From Itineraries to Transactions
PhocusWire reports that AI travel agent Vayo has added booking to its capabilities, letting users complete a full trip reservation inside a conversation rather than only receiving suggestions. The update pushes consumer travel AI from planning into the transaction itself, where accuracy and conversion rates decide whether it works.